Investigation and Restoration of BEST1 Activity in Patient-derived RPEs with Dominant Mutations

Overview

Journal Sci Rep

Specialty Science

Date 2019 Dec 15

PMID 31836750

Citations 23

Authors

Changyi Ji

Yao Li

Alec Kittredge

Austin Hopiavuori

Nancy Ward

Peng Yao

Yohta Fukuda

Yu Zhang

Stephen H Tsang

Tingting Yang

Affiliations

Soon will be listed here.

Abstract

BEST1 is a Ca-activated Cl channel predominantly expressed in retinal pigment epithelium (RPE), and over 250 genetic mutations in the BEST1 gene have been identified to cause retinal degenerative disorders generally known as bestrophinopathies. As most BEST1 mutations are autosomal dominant, it is of great biomedical interest to determine their disease-causing mechanisms and the therapeutic potential of gene therapy. Here, we characterized six Best vitelliform macular dystrophy (BVMD)-associated BEST1 dominant mutations by documenting the patients' phenotypes, examining the subcellular localization of endogenous BEST1 and surface Ca-dependent Cl currents in patient-derived RPEs, and analyzing the functional influences of these mutations on BEST1 in HEK293 cells. We found that all six mutations are loss-of-function with different levels and types of deficiencies, and further demonstrated the restoration of Ca-dependent Cl currents in patient-derived RPE cells by WT BEST1 gene supplementation. Importantly, BEST1 dominant and recessive mutations are both rescuable at a similar efficacy by gene augmentation via adeno-associated virus (AAV), providing a proof-of-concept for curing the vast majority of bestrophinopathies.

Citing Articles

Expanding the Mutation Spectrum for Inherited Retinal Diseases.

Lynn J, Huang S, Trigler G, Kingsley R, Coussa R, Bennett L Genes (Basel). 2025; 16(1).

PMID: 39858579 PMC: 11764958. DOI: 10.3390/genes16010032.

Neurotransmitter-bound bestrophin channel structures reveal small molecule drug targeting sites for disease treatment.

Owji A, Dong J, Kittredge A, Wang J, Zhang Y, Yang T Nat Commun. 2024; 15(1):10766.

PMID: 39737942 PMC: 11685958. DOI: 10.1038/s41467-024-54938-z.

Ion channels research in hPSC-RPE cells: bridging benchwork to clinical applications.

Xu P, Zou W, Yin W, Chen G, Gao G, Zhong X J Transl Med. 2024; 22(1):1073.

PMID: 39604931 PMC: 11600670. DOI: 10.1186/s12967-024-05769-5.

GAD65 tunes the functions of Best1 as a GABA receptor and a neurotransmitter conducting channel.

Wang J, Owji A, Kittredge A, Clark Z, Zhang Y, Yang T Nat Commun. 2024; 15(1):8051.

PMID: 39277606 PMC: 11401937. DOI: 10.1038/s41467-024-52039-5.

Evaluating precision medicine approaches for gene therapy in patient-specific cellular models of Bietti crystalline dystrophy.

Li Y, Yang R, Li Y, Hsu C, Jenny L, Kong Y JCI Insight. 2024; 9(16).

PMID: 39171529 PMC: 11343589. DOI: 10.1172/jci.insight.177231.

References

Marmorstein A, Cross H, Peachey N . Functional roles of bestrophins in ocular epithelia. Prog Retin Eye Res. 2009; 28(3):206-26. PMC: 2740978. DOI: 10.1016/j.preteyeres.2009.04.004. View

Sun H, Tsunenari T, Yau K, Nathans J . The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci U S A. 2002; 99(6):4008-13. PMC: 122639. DOI: 10.1073/pnas.052692999. View

Allikmets R, Seddon J, Bernstein P, Hutchinson A, Atkinson A, Sharma S . Evaluation of the Best disease gene in patients with age-related macular degeneration and other maculopathies. Hum Genet. 1999; 104(6):449-53. DOI: 10.1007/s004390050986. View

Guziewicz K, Cideciyan A, Beltran W, Komaromy A, Dufour V, Swider M . gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure. Proc Natl Acad Sci U S A. 2018; 115(12):E2839-E2848. PMC: 5866594. DOI: 10.1073/pnas.1720662115. View

Marmorstein A, Marmorstein L, Rayborn M, Wang X, Hollyfield J, Petrukhin K . Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2000; 97(23):12758-63. PMC: 18837. DOI: 10.1073/pnas.220402097. View

Burgess R, Millar I, Leroy B, Urquhart J, Fearon I, De Baere E . Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet. 2008; 82(1):19-31. PMC: 2253971. DOI: 10.1016/j.ajhg.2007.08.004. View

Mao H, James Jr T, Schwein A, Shabashvili A, Hauswirth W, Gorbatyuk M . AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum Gene Ther. 2010; 22(5):567-75. PMC: 3131806. DOI: 10.1089/hum.2010.140. View

Ji C, Kittredge A, Hopiavuori A, Ward N, Chen S, Fukuda Y . Dual Ca-dependent gates in human Bestrophin1 underlie disease-causing mechanisms of gain-of-function mutations. Commun Biol. 2019; 2:240. PMC: 6591409. DOI: 10.1038/s42003-019-0433-3. View

Hartzell H, Qu Z, Yu K, Xiao Q, Chien L . Molecular physiology of bestrophins: multifunctional membrane proteins linked to best disease and other retinopathies. Physiol Rev. 2008; 88(2):639-72. DOI: 10.1152/physrev.00022.2007. View

10.

Johnson A, Guziewicz K, Lee C, Kalathur R, Pulido J, Marmorstein L . Bestrophin 1 and retinal disease. Prog Retin Eye Res. 2017; 58:45-69. PMC: 5600499. DOI: 10.1016/j.preteyeres.2017.01.006. View

11.

Goehring A, Lee C, Wang K, Michel J, Claxton D, Baconguis I . Screening and large-scale expression of membrane proteins in mammalian cells for structural studies. Nat Protoc. 2014; 9(11):2574-85. PMC: 4291175. DOI: 10.1038/nprot.2014.173. View

12.

Kemp C, Jacobson S, Roman A, Sung C, Nathans J . Abnormal rod dark adaptation in autosomal dominant retinitis pigmentosa with proline-23-histidine rhodopsin mutation. Am J Ophthalmol. 1992; 113(2):165-74. DOI: 10.1016/s0002-9394(14)71529-6. View

13.

Bennett J, Wellman J, Marshall K, McCague S, Ashtari M, DiStefano-Pappas J . Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016; 388(10045):661-72. PMC: 5351775. DOI: 10.1016/S0140-6736(16)30371-3. View

14.

Noorwez S, Sama R, Kaushal S . Calnexin improves the folding efficiency of mutant rhodopsin in the presence of pharmacological chaperone 11-cis-retinal. J Biol Chem. 2009; 284(48):33333-42. PMC: 2785176. DOI: 10.1074/jbc.M109.043364. View

15.

Daiger S, Bowne S, Sullivan L . Genes and Mutations Causing Autosomal Dominant Retinitis Pigmentosa. Cold Spring Harb Perspect Med. 2014; 5(10). PMC: 4588133. DOI: 10.1101/cshperspect.a017129. View

16.

Shin Y, Moiseyev G, Chakraborty D, Ma J . A Dominant Mutation in Rpe65, D477G, Delays Dark Adaptation and Disturbs the Visual Cycle in the Mutant Knock-In Mice. Am J Pathol. 2017; 187(3):517-527. PMC: 5389371. DOI: 10.1016/j.ajpath.2016.11.004. View

17.

Yang T, Justus S, Li Y, Tsang S . BEST1: the Best Target for Gene and Cell Therapies. Mol Ther. 2015; 23(12):1805-9. PMC: 4700113. DOI: 10.1038/mt.2015.177. View

18.

Davidson A, Millar I, Urquhart J, Burgess-Mullan R, Shweikh Y, Parry N . Missense mutations in a retinal pigment epithelium protein, bestrophin-1, cause retinitis pigmentosa. Am J Hum Genet. 2009; 85(5):581-92. PMC: 2775838. DOI: 10.1016/j.ajhg.2009.09.015. View

19.

Kohl S, Zobor D, Chiang W, Weisschuh N, Staller J, Menendez I . Mutations in the unfolded protein response regulator ATF6 cause the cone dysfunction disorder achromatopsia. Nat Genet. 2015; 47(7):757-65. PMC: 4610820. DOI: 10.1038/ng.3319. View

20.

Bowne S, Humphries M, Sullivan L, Kenna P, Tam L, Kiang A . A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvement. Eur J Hum Genet. 2011; 19(10):1074-81. PMC: 3190249. DOI: 10.1038/ejhg.2011.86. View